Alice J.A.M. Sijts

Dr. Alice J.A.M. Sijts


Research Focus & Metrics

Academic Career Length

38Years (1989-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2013 in Immunity
Verified
Journal Article
Closed access
DZDietmar Zaiss
Dietmar Zaiss
JLJorg van Loosdregt
Jorg van Loosdregt
AGAndrea Gorlani
Andrea Gorlani
CBCornelis P.J. Bekker
Cornelis P.J. Bekker
AGAndrea Gröne
Andrea Gröne
ASAlice J.A.M. Sijts
Alice J.A.M. Sijts

1 August 2013 in Immunity
Verified
Journal Article
Closed access
JLJorg van Loosdregt
Jorg van Loosdregt
VFVeerle Fleskens
Veerle Fleskens
JFJuan Fu
Juan Fu
ABArjan B. Brenkman
Arjan B. Brenkman
CBCornelis P.J. Bekker
Cornelis P.J. Bekker
PCPaul J. Coffer
Paul J. Coffer

1 August 2013 in Immunity
Verified
Journal Article
Closed access
JLJorg van Loosdregt
Jorg van Loosdregt
VFVeerle Fleskens
Veerle Fleskens
MTMachteld M. Tiemessen
Machteld M. Tiemessen
MMMichal Mokry
Michal Mokry
RBRuben van Boxtel
Ruben van Boxtel
PCPaul J. Coffer
Paul J. Coffer

1 January 2001 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
JKJan H. Kessler
Jan H. Kessler
NBNico J. Beekman
Nico J. Beekman
SBSandra A. Bres-Vloemans
Sandra A. Bres-Vloemans
PVPauline Verdijk
Pauline Verdijk
PVPeter A. van Veelen
Peter A. van Veelen
CMCornelis J.M. Melief
Cornelis J.M. Melief
We report the efficient identification of four human histocompatibility leukocyte antigen (HLA)-A*0201–presented cytotoxic T lymphocyte (CTL) epitopes in the tumor-associated antigen PRAME using an improved “reverse immunology” strategy. Next to motif-based HLA-A*0201 binding prediction and actual binding and stability assays, analysis of in vitro proteasome-mediated digestions of polypeptides encompassing candidate epitopes was incorporated in the epitope prediction procedure. Proteasome cleavage pattern analysis, in particular determination of correct COOH-terminal cleavage of the putative epitope, allows a far more accurate and selective prediction of CTL epitopes. Only 4 of 19 high affinity HLA-A*0201 binding peptides (21%) were found to be efficiently generated by the proteasome in vitro. This approach avoids laborious CTL response inductions against high affinity binding peptides that are not processed and limits the number of peptides to be assayed for binding. CTL clones induced against the four identified epitopes (VLDGLDVLL, PRA100–108; SLYSFPEPEA, PRA142–151; ALYVDSLFFL, PRA300–309; and SLLQHLIGL, PRA425–433) lysed melanoma, renal cell carcinoma, lung carcinoma, and mammary carcinoma cell lines expressing PRAME and HLA-A*0201. This indicates that these epitopes are expressed on cancer cells of diverse histologic origin, making them attractive targets for immunotherapy of cancer.

1 August 1996 in Immunity
Verified
Journal Article
Closed access
FOFerry Ossendorp
Ferry Ossendorp
MEMaren Eggers
Maren Eggers
ANAnne Neisig
Anne Neisig
TRThomas Ruppert
Thomas Ruppert
MGMarcus Groettrup
Marcus Groettrup
CMCornelis Melief
Cornelis Melief

1 February 1995 in The Journal of Immunology
Verified
Journal Article
Open access
PDF file
ANA Neisig
A Neisig
JRJ Roelse
J Roelse
ASAlice J.A.M. Sijts
Alice J.A.M. Sijts
FOF Ossendorp
F Ossendorp
MFMariet Feltkamp
Mariet Feltkamp
JNJacques Neefjes
Jacques Neefjes
The MHC-encoded transporter associated with Ag presentation (TAP) translocates peptides from the cytosol to the ER lumen, where association with MHC class I molecules occurs. The MHC class I/peptide complex is subsequently transported to the cell surface for presentation to CD8+T cells. We studied TAP-dependent translocation of defined MHC class I presentable murine peptides by competition for translocation of a radiolabeled model peptide, to address whether efficient peptide presentation by MHC class I molecules is preceded by equal efficient peptide translocation by TAP. Surprisingly, we observed that four immunodominant viral peptides of 16 peptides tested were very inefficiently transported by TAP. Inefficient translocation could be overcome by substitution of a proline residue present at position 3 in the peptides. Furthermore, addition of natural flanking amino acids directly surrounding a poorly transported peptide could considerably improve translocation by TAP. Our data suggest that some peptides are efficiently transported by TAP in their optimal size for MHC class I binding, whereas other peptides are transported as larger peptide fragments that need further trimming in the ER for MHC class I binding.